Francisco Leon Email & Phone Number

Washington, DC, US

Founder and CEO of Tolerance Bio, a biotech start-up focused on improving healthspan by restoring and preserving the function of the thymus, a key regulator of immune tolerance. https://www.tolerancebio.com/

Co-founder of Paulex Bio, a clinical-stage biotech company working towards a world without diabetes. Paulex is developing preventative and regenerative therapies for Type-1 and Type-2 Diabetes. https://paulexbio.com/

Co-Founder of Avalor Therapeutics, a biotech start-up developing breakthrough precision medicine for chronic inflammation. Avalor is initially focused on disease modification in osteoarthritis. https://avalortx.com/

Praetorian Bio is a biotech startup in stealth mode, developing a revolutionary preventative approach for oral health.

Boston, Massachusetts, US

Board Director at Lapix Therapeutics, clinical-stage biopharma company developing novel, orally bioavailable immune system restoration therapies for autoimmune diseases and oncology. https://lapix.com/

Vaxdyn is a biotechnology company located in Seville, Spain, developing a vaccine platform for antibiotic-resistant bacteria, such as Klebsiella, Acinetobacter and Pseudomonas. Our goal is to decrease the impact on public health of infections caused by drug-resistant pathogens. https://vaxdyn.com/

Indianapolis, IN, US

Glutenostics commercializes rapid detection assays (GlutenDetect Stool and Gluten Detect Urine) and lab-based assays (iVYCHECK lateral flow test, iVYDAL ELISA) to help people avoiding gluten to be more compliant with their diets. https://glutendetect.us/

Company ideation and consultancy firm.

Paris, France, FR

After the acquisition, I help transition and advance the Provention Bio pipeline in Sanofi, focusing on Tzield (PROTECT completion and regulatory activities, intellectual property development, life cycle).

Co-Founder, Chief Scientific Officer, former Board Director (2018-2019), former Chairman of the Scientific Advisory Board (2017). Provention Bio was acquired by Sanofi in April 2023.Provention was a clinical-stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics and cutting edge solutions to intercept and.

US

Provided advice on innovative clinical trials in celiac disease.

Co-founded Celimmune, an immunotherapy company focused on gastrointestinal autoimmunity. CEO and Chief Medical Officer from Feb 2015 to November 2017, when Amgen acquired Celimmune following completion of Phase 2 clinical trials of AMG 714 (anti-IL-15 mAb) in celiac and refractory celiac disease Type II (pre-EATL/intestinal T cell lymphoma).

Raritan, New Jersey, US

Founded the Immunology Translational Medicine team at Centocor, later Janssen. Responsible for translational strategies and early clinical development of biologic and small molecule therapies for immune-mediated diseases (Phase 0 to proof-of-concept) at Johnson & Johnson.

US

Head of Clinical Development. Early and Late Development including Regulatory. Celiac Disease, Crohn's Disease. Led clinical aspects of the out-licensing of larazotide acetate to Cephalon/TEVA.

Gaithersburg, Maryland, US

Inflammation therapeutic area, focus in Asthma, serving as development leader for the anti-IL-9 and anti-IL5R programs (clinical lead for Phase 1 FIH study for benralizumab, FASENRA) as well as earlier stage programs. Contributed to biomarker efforts in mucosal vaccines (FluMist), life-cycle management and corporate and business development activities.

Lawrence Township, NJ, US

Early development of immune modulators in Immunology and Oncology. Phase I-IIa, biomarkers, POC, clinical pharmacology. Focus on costimulation (abatacept/ORENCIA sBLA, belatacept/NULOJIX biomarker patents, immune monitoring of ipilimumab/YERVOY responses, in-licensing discussions for nivolumab/OPDIVO with Ono) and chemokine receptors (development team.

Bethesda, MD, US

Postdoctoral Research Fellow at the Laboratory of Clinical Investigation (Head: Dr. Warren Strober), reorganized in 2004 as Laboratory of Molecular Immunology (Head: Dr. Phil Murphy), at the National Institutes of Allergy and Infectious Diseases, National Institutes of Health (LCI-LMI/NIAID/NIH), Bethesda, MD, Feb 2002- Sept 2004. Study of the role of.

Phd, Mucosal Immunology

Specialist, Clinical Immunology

Md, Allergy And Immunology Residency Program